INVESTIGATION OF 2548G>A LEPTINE GENE POLYMORPHIC VARIANT IMPACT ON RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Authors

  • Tyzhnenko T. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine; V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0003-1223-6240
  • Misiura K. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0002-0258-9109
  • Kravchun N. O. Multidisciplinary medical center "Life Park" https://orcid.org/0000-0001-7222-8424
  • Gorshunska M. Yu. Kharkiv Medical Academy of postgraduate education of the Ministry of health of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0002-4402-9441
  • Pochernyaev A. K. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine; Poltava Scientific Research Forensic Center of the Ministry of Internal Affairs of Ukraine, Poltava, Ukraine https://orcid.org/0000-0001-9520-4492
  • Krasova N. S. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0002-7113-7616
  • Gladkih A. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Leshchenko Zh. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0002-6141-689X
  • Fedorova G. V. University of South Bohemia in České Budějovice, Vodňany, Czech Republic https://orcid.org/0000-0001-5492-7459
  • Plohotnichenko O. O. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Hromakovska O. B. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Kolesnikova A. O. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0002-3799-0402
  • Jаnsen E. National Institute for Public Health and the Environment, Bilthoven, The Netherlands
  • Karachentsev Yu. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine https://orcid.org/0000-0003-1317-6999
  • Poltorak V. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0002-3717-4413

DOI:

https://doi.org/10.21856/j-PEP.2022.3.06

Keywords:

type 2 diabetes mellitus, non-alcoholic fatty liver disease, leptin, single nucleotide polymorphisms

Abstract

Background. It is known that single nucleotide polymorphisms (SNPs) in adipokine genes can influence the development of pathological conditions associated with obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease and their complications. In this study, we aimed to investigate the link between common -2548G>A (rs7799039) promoter variant of the human leptin gene (LEP) with leptin levels in type 2 diabetes patients with non-alcoholic fatty liver diseasese. Materials and methods. 61 patients with T2D aged from 28 to 80 years old (34 men/27 women, age 56.40±0.62 yrs, diabetes duration 7.72±0.45 yrs, BMI 32.20±0.43 kg/m2, WHR 1,00 ±0,01, HbA1c 7.80±0.19 %) with varying degrees of glycemic control and overweight, without renal insufficiency and 51 sex and age-match control subjects were examined. Genotyping according to SNP LEP 2548G>A was performed using the polymerase chain reaction method with appropriate primers and HhaI endonuclease. Results. In our study of  T2DM patients with NAFLD compared to T2DM patients without NAFLD features of dyslipidemia i.e. significant increase in triglycerides (p <0,001), LDL cholesterol (p <0,1), lower HDL cholesterol ( p <0.001) were found. Stratification of the diabetic patients in the presence and absence of NAFLD showed  more pronounced increase in circulating leptin levels in the presence of NAFLD (84.73 ± 13.80 vs. 52.57 ± 6.86 ng / ml, respectively), (p <0.01), which justifies the feasibility of using this indicator for further needs as a diagnostic parameter of the above complication. In our study in GG carriers genotype of the G2548A LEP gene polymorphic locus type 2 diabetes patients with NAFLD the highest level of leptin was observed (159.15 ng/ml), compared to other genotypes. Thus, it can be assumed that the G allele is associated with increased leptin levels in the blood of patients with NAFLD. This study showed that women with type 2 diabetes mellitus carrying the GG genotype with the G-2458A polymorphic variant of the LEP gene have 3.4 times higher leptin levels than men carrying the same genotype (p<0.03). The data obtained regarding the 2548G>A polymorphic variant of the LEP gene can be used as a basis for personalized prevention and the formation of risk groups for the development of NAFLD.

References

Pouwels S, Sakran N, Graham Y, et al. BMC Endocr Disord 2022;22(1): 63.

Vernon G, Baranova A, Younossi ZM. Aliment Pharmacol Ther 2011;34: 274-285.

Baltieri L, Chaim EA, Chaim FM. Arq Gastroenterol 2018;55: 247-251.

Schuppan D, Surabattula R, Wang XY. J Hepatol 2018;68: 238-250.

Wong T, Wong RJ, Gish RG. Gastroenterol Hepatol (NY) 2019;15(2): 83-89.

Marchisello S, Di Pino A, Scicali R, et al. Int J Mol Sci 2019;20(8): 1948.

Yu J, Marsh S, Hu J, Feng W, Wu C. Gastroenterol Res Pract. 2016;2016:2862173.

Greenberg AS, Obin MS. Am J Clin Nutr 2006;83(2): 461S-465S.

Estep JM, Baranova A, Hossain N, et al. Obes Surg 2009;19: 617-624.

Moon HS, Dalamaga M, Kim SY, et al. Endocr Rev 2013;34: 377-412.

Wrуblewski A, Strycharz J, Sґwiderska E. Nutrients 2019;11: 1872.

Lee S, Kuk JL, Boesch C, Arslanian S. Appl Physiol Nutr Metab 2017;42(8): 829-833.

Maskarinec G, Garber AK, Wong MC, et al. Obes Sci Pract 2021;7: 53-62.

Mammes O, Betoulle D, Aubert R, et al. Diabetes 1998;47: 487-489.

Ortega-Azorín C, Coltell O, Asensio EM, et al. Nutrients 2019;11: 2751.

Sabi EM, Bin Dahman LS, Mohammed AK, et al. Medicina (Kaunas) 2022;58(3): 346.

Sharma R, Agrawal S, Saxena A, et al. Genes Nutr 2013;8(6): 611-621.

Zayani N, Omezzine A, Boumaiza I, et al. J Clin Lab Anal 2017;31(6).

Alnry A, Gad H, Hegazy G, Shaker O. Turk J Med Sci 2016;46(5): 1335-1340.

Manriquez V, Aviles J, Salazar L, et al. Mol Diagn Ther 2018;22(1): 101-113.

Crescenti A, Sola R, Valls RM, et al. Genes Nutr 2013;8(1): 127-136.

Gregoor JG, van der Weide J, Loovers HM, et al. Psychiatr Genet 2010;20(6): 311-316.

Szanto KB, Li J, Cordero P, Oben JA. Diab Metab Syndr Obes 2019;12: 357-367.

Chalasani N, Younossi Z, Lavine JE, et al. Hepatology 2012;55(6): 2005-2023.

Armitage P, Berry G. Statistical methods in medical research. 4rd ed., Blackwell Scientific Publications, 2001: 826 p.

Chen Z, Yu R, Xiong Y, et al. Lipids Health Dis 2017;16(1): 203.

Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Ann Intern Med 2010;152: 93-100.

Moon HS, Dalamaga M, Kim SY, et al. Endocr Rev 2013;34: 377-412.

Mantzoros CS, Magkos F, Brinkoetter M, et al. Am J Physiol Endocrinol Metab 2011;301: E567-E584.

Dalamaga M, Chou SH, Shields K, et al. Cell Metab 2013;18: 29-42.

Rotundo L, Persaud A, Feurdean M, et al. Clin Mol Hepatol 2018;24(4): 392-401.

Ben Ali S, Kallel A, Ftouhi B, et al. Clin Biochem 2009;42(7-8): 584-588.

Constantin A. et al. Biochem Biophys Res Commun 2010;391: 282-286.

Dagdan B, Chuluun -Erdene A, Sengeragchaa O, et al. Med Sci (Basel) 2018;7(1): E3.

Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. Horm Metab Res 2002;34(7): 355-359.

Nieters A, Becker N, Linseisen J. Eur J Nutr 2002;41(5): 210-221.

Nawfal Hussein Amhe, Fawzi Hassan Zayr Al-Fahdawi, Ali Gheisarzadeh, A.A Hatamnia PJMHS 2022;16 (04): 927-929

Sabi EM, Bin Dahman LS, Mohammed AK, et al. Medicina 2022;58: 346.

Mammes O, Betoulle D, Aubert R, et al. Ann Hum Genet 2000;64: 391-394.

Wang TN, Huang MC, Chang WT, et al. Obesity (Silver Spring) 2006;14: 183-187.

Jiang Y, Wilk JB, Borecki I, et al. Am J Hum Genet 2004;75: 220-230.

Yang M, Peng S, Li W, et al. Scientific Reports 2016;6: 23948.

Mattevi VS, Zembrzuski VM, Hutz MH. Int J Obes Rel Metab Res 2002;26: 1179-1185.

Portoles O, Sorli JV, Frances F, et al. Eur J Epidemiol 2006;21: 605-612.

Hinuy HM, Hirata MH, Forti N, et al. Arq Bras Endocrinol Metab 2008;52(4): 1-6.

Le Stunff C, Le Bihan C, Schork NJ, Bougneres P. Diabetes 2000;49: 2196-2200.

Ren W, Zhang SH, Wu J, Ni YX. Chin Med J (Engl) 2004;117: 558-561.

Yiannakouris N, Melistas L, Yannakoulia M, et al. Hormones (Athens) 2003;2: 229-236.

Mammes O, Betoulle D, Aubert R, et al. Ann Hum Genet 2000;64: 391-394.

Menezes CA, Alves Junior ER, Costa GNO, et al. Rev Paul Pediatr 2022;40: e2021030.

Downloads

Published

2022-09-15

How to Cite

Tyzhnenko, T., Misiura, K., Kravchun, N., Gorshunska, M., Pochernyaev, A., Krasova, N., Gladkih, A., Leshchenko, Z., Fedorova, G., Plohotnichenko, O., Hromakovska, O., Kolesnikova, A., Jansen, E., Karachentsev, Y., & Poltorak, V. (2022). INVESTIGATION OF 2548G>A LEPTINE GENE POLYMORPHIC VARIANT IMPACT ON RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS . Problems of Endocrine Pathology, 79(3), 42-52. https://doi.org/10.21856/j-PEP.2022.3.06

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

<< < 1 2 3 > >>